{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T01:00:47Z","timestamp":1760403647766,"version":"build-2065373602"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ijantimicag.2023.106897","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T15:53:48Z","timestamp":1687190028000},"page":"106897","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting"],"prefix":"10.1016","volume":"62","author":[{"given":"Tommaso","family":"Clemente","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Poli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecka","family":"Papaioannu Borjesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Bresciani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camilla","family":"Muccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Canetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Candela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Bossolasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Hasson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106897_bib0001","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(14)60604-8","article-title":"Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration","volume":"384","author":"Smith","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0002","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/QAI.0000000000000825","article-title":"Long-term mortality in HIV-infected individuals 50 years or older: a nationwide, population-based cohort study","volume":"71","author":"Legarth","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0003","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/S2352-3018(17)30066-8","article-title":"Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies","volume":"4","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0004","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7954","article-title":"Comparison of overall and comorbidity-free life expectancy between insured adults with and without HIV infection, 2000\u20132016","volume":"3","author":"Marcus","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0005","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0006","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1016\/S2352-3018(18)30043-2","article-title":"Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study","volume":"5","author":"Ryom","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0007","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/infdis\/jit043","article-title":"Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study","volume":"207","author":"Ryom","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0008","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1093\/infdis\/jiz369","article-title":"Use of contemporary protease inhibitors and risk of incident chronic kidney disease in persons with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study","volume":"220","author":"Ryom","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0009","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1097\/QAD.0000000000001018","article-title":"Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons","volume":"30","author":"Ryom","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0010","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s11481-019-09886-7","article-title":"CNS neurotoxicity of antiretrovirals","volume":"16","author":"Lanman","year":"2021","journal-title":"J Neuroimmune Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0011","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/381783","article-title":"Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?","volume":"189","author":"Fontas","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0012","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/COH.0000000000000248","article-title":"Tenofovir and bone health","volume":"11","author":"Grant","year":"2016","journal-title":"Curr Opin HIV AIDS"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0013","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"year":"2022","series-title":"Guidelines version 11.1","key":"10.1016\/j.ijantimicag.2023.106897_bib0014"},{"year":"2022","series-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV","key":"10.1016\/j.ijantimicag.2023.106897_bib0015"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0016","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir\u2013rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"Llibre","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0017","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0018","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0019","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(15)00097-3","article-title":"Dual treatment with atazanavir\u2013ritonavir plus lamivudine versus triple treatment with atazanavir\u2013ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial","volume":"15","author":"Perez-Molina","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0020","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/cix734","volume":"65","author":"Pulido","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0021","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0022","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1080\/21505594.2021.2004743","article-title":"Persistent low-level viremia in persons living with HIV undertreatment: an unresolved status","volume":"12","author":"Crespo-Bermejo","year":"2021","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2023.106897_bib0023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciac762","article-title":"Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European multicenter cohort","volume":"76","author":"Elvstam","year":"2023","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923001760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:48:27Z","timestamp":1760377707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923001760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0924857923001760"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106897","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106897","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106897"}}